Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

clinical trial

Details

Instance of: clinical trial
Start time: October 2013
End time: April 2014
Country: United States
Main subject: combination therapy, ledipasvir
clinical trial phase: phase II clinical trial
minimum age: 18
number of participants: 101
research intervention: sofosbuvir
study type: interventional study
title: A Phase 2, Randomized, Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination With Ribavirin or GS-9669 250 mg or GS-9669 500 mg in Naive or Treatment-Experienced Cirrhotic Subjects With Chronic Genotype 1 HCV Infection

Nothing in the MetaHistoryBook collection references this item yet.